soul trial oral semaglutide cardiovascular outcomes results 2024 2025 nejm 🧿 is the first oral GLP-1 RA proven to reduce MACE in high-risk T2DM patients, extending protection beyond injectable formulations. Trial: Oral Semaglutide & Cardiovascular in T2DM soul trial oral semaglutide cardiovascular

Yes - NativePath is a real company with a real product and real contact information

Once in circulation, GLP-1 exerts powerful metabolic effects: it enhances glucose-dependent insulin secretion from the pancreas, suppresses excess glucagon, and signals the hypothalamic nuclei in the brain to promote satiety

Tuberculin syringes: These are marked in mL with 0.01 mL gradations

The slight potential reduction comes from lower peak concentrations, but this is partially offset by higher trough levels providing more consistent appetite suppression

The safest patient-friendly answer is: possibly, in selected patientsespecially those with existing diabetic retinopathy, especially early after starting treatment, and especially when glucose improves rapidly

Timing doses is crucial since these medicines remain active in the body for several days